
isSCC
isSCC
US
isSCC
China (MRCT)52
BCC
BCC
US
Liver Cancer1 (Basket) **
Liver Cancer1 (Basket) **
US
Liver Cancer1 (Basket) **
China (MRCT)3
Liver Cancer, combo with anti-PD-(L)1
Liver Cancer, combo with anti-PD-(L)1
US

isSCC
BCC
Liver Cancer1 (Basket) **
Liver Cancer, combo with anti-PD-(L)1
Delivery Platform:
PNP-IT
PNP-IT
PNP-IT
PNP-IT
Commercial Rights:
Global
Global
Global
Global
Our core product candidate, STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. We are developing STP705 for NMSC including isSCC, dermal fibrosis and solid liver tumors.
STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC).
Liver Cancer1 (Basket)**
Liver Cancer1 (Basket)**
US
Liver Cancer1 (Basket)**
China (MRCT)4
cSCC
cSCC
US
NSCLC
NSCLC
US
Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1
Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1
US

Liver Cancer1 (Basket)**
cSCC
NSCLC
Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1
Delivery Platform:
PNP-IV
PNP-IV
PNP-IV
PNP-IV
Commercial Rights:
Global
Global
Global
Global
Our key product candidate STP707 is, like STP705, a dual TGF-ß1/COX-2 inhibitor that uses our PNP delivery platform. Whereas STP705 uses a formulation of our PNP delivery platform optimized for local administration (i.e., directly to the site of disease), STP707 uses a formulation of our PNP delivery platform optimized for systemic administration. Thus, STP707 may be administered intravenously for treatment systemically, including solid tumor or fibrotic tissue in the liver or lung.
Looking beyond our initial target indications for local administration for STP705, we are developing STP707 for the treatment of liver cancer, multiple solid tumors and liver fibrosis via systemic administrations as well as for treatment of lung cancer and lung fibrosis.
Pan Cancer
Pan Cancer
US

Pan Cancer
Delivery Platform:
PNP-IT/IV
Commercial Rights:
Global
STP355 comprises siRNA simultaneously targeting TGF-ß1 and VEGFR2, a target gene well-validated for its involvement in tumor angiogenesis and metastasis, formulated using our PNP delivery platform for systemic administration. We are developing STP355 for the treatment of multiple cancer types, including breast cancer, melanoma and colorectal cancer. We plan to file an IND for STP355 in the U.S. in the first half of 2022.
Head & Neck Cancer/Bladder Cancer
Head & Neck Cancer/Bladder Cancer
US

Head & Neck Cancer/Bladder Cancer
Delivery Platform:
PNP-IT / IV
Commercial Rights:
Global
STP369 comprises siRNAs targeting BCL-xL and MCL-1, which are both validated tumorigenesis-associated genes, and formulated with our PNP delivery platform for intravenous or intra-tumoral injection administration. We are developing STP369 for the treatment of head and neck cancer and bladder cancer. We are also exploring use of STP369 in combination therapy with platinum-based chemotherapy (cisplatin) due to its widespread use in treating patients to evaluate the potential for STP369 to improve the efficacy of cisplatin or replace its use. We anticipate filing an IND in the second half of 2022.

Delivery Platform:
PNP-IV
Commercial Rights:
Global
STP779 comprises siRNA targeting TGF-ß1 and SULF-2, another validated tumorigenesis-associated gene, formulated with our PNP delivery platform for systemic administration. We are developing STP779 for the treatment of liver cancer, lung cancer and pancreatic cancer. We maintain the global rights to develop and commercialize STP779.
Breast Cancer
Breast Cancer

Breast Cancer
Delivery Platform:
PNP-IT / IV
Commercial Rights:
Global
STP902 comprises siRNA targeting RAF-1, a validated tumorigenesis-associated gene, formulated with our PNP delivery platform for intravenous and intra-tumoral injection; administration. We are developing STP902 for the treatment of breast cancer. We maintain the global rights to develop and commercialize STP902.

Keloid Scarless Healing**
Keloid Scarless Healing**
US
Hypertrophic Scarring
Hypertrophic Scarring
US
Hypertrophic Scarring
China(MRCT)5
Hypertrophic Scarring
China

Keloid Scarless Healing**
Hypertrophic Scarring
Delivery Platform:
PNP-ID
PNP-ID
Commercial Rights:
Global
Global
In addition to our initial target indications, we are developing STP705 for treatment of hepatocellular carcinoma and cholangiocarcinoma (HCC/CCA).
We are also developing combination therapies with STP705 and immune checkpoint inhibitors for liver cancer.
Liver Fibrosis (PSC)
Liver Fibrosis (PSC)
US
Liver Fibrosis (PSC)

Liver Fibrosis (PSC)
Lung FibrosisDelivery Platform:
PNP-IV
PNP-IV
Commercial Rights:
Global
Global
Our key product candidate STP707 is, like STP705, a dual TGF-ß1/COX-2 inhibitor that uses our PNP delivery platform. Whereas STP705 uses a formulation of our PNP delivery platform optimized for local administration (i.e., directly to the site of disease), STP707 uses a formulation of our PNP delivery platform optimized for systemic administration. Thus, STP707 may be administered intravenously for treatment systemically, including solid tumor or fibrotic tissue in the liver or lung.
Looking beyond our initial target indications for local administration for STP705, we are developing STP707 for the treatment of liver cancer, multiple solid tumors and liver fibrosis via systemic administrations as well as for treatment of lung cancer and lung fibrosis.

Fat Sculpting
Fat Sculpting
US

Fat Sculpting
Delivery Platform:
PNP-ID
Commercial Rights:
Global

Influenza
Influenza
US

Influenza
Delivery Platform:
Airway / PNP-IV
Commercial Rights:
OL China
STP702 comprises siRNA simultaneously targeting the M1 and PA influenza viral gene sequences formulated with our PNP delivery platform. We are developing STP702 for treatment of influenza.
Covid-19
Covid-19
US

Covid-19
Delivery Platform:
Airway / PNP-IV
Commercial Rights:
Global
STP908 comprises siRNA targeting the SARS-CoV-2 ORF1Ab and N-protein genes formulated with our PNP delivery platform. We are developing STP908 for the treatment of COVID-19 and other diseases caused by SARS coronaviruses for intravenous and inhalation administration. STP908 is directed to providing prophylactic options for uninfected people as well as therapeutic options for patients to both prevent hospitalization or treat hospitalized patients. We have previously collaborated with researchers at the Boston University National Emerging Infectious Disease Laboratory on preclinical research relating to STP908.
Covid-19 Vaccine
Covid-19 Vaccine
US

Covid-19 Vaccine
Delivery Platform:
LNP Intramuscular
Commercial Rights:
Global
Instead of applying RNAi technology like the candidates described above, RIM730 is being developed by RNAimmune as a prophylactic mRNA vaccine candidate for prevention of COVID-19 using our PLNP platform targeting certain mutations of the SARS-CoV-2 virus.
HPV/Cervical Cancer
HPV/Cervical Cancer

HPV/Cervical Cancer
Delivery Platform:
PNP-IV/Topical
Commercial Rights:
Global
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. We are developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.
We maintain the global rights to develop and commercialize STP909.

Anticoagulant
Anticoagulant
US

Anticoagulant
Delivery Platform:
GalAhead™ subcutaneous
Commercial Rights:
Global
Another key product candidate is STP122G, formulated using our GalAhead™ platform and targeting Factor XI, which is being developed for anticoagulant therapy for use in the many different therapeutic settings where antithrombotic therapeutics are needed.
STP122G comprises RNAi triggers targeting Factor XI. Factor XI is a plasma glycoprotein that is primarily synthesized in the liver and is part of the coagulation cascade, playing a role in clot stabilization and expansion. Factor XI is an attractive target for anticoagulant therapy because while individuals deficient in Factor XI have reduced risk of thrombosis-related events, they exhibit little increase in bleeding, thus providing the potential to separate antithrombotic activity from bleeding risk.

Delivery Platform:
GalAhead™ subcutaneous
Commercial Rights:
Global
STP133G comprises RNAi triggers simultaneously targeting PCSK9 and ApoC3, formulated with our GalAhead™ delivery platform for subcutaneous administration. We are developing STP133G as part of our cardiometabolic disease program.
Hypercholesterolemia
Hypercholesterolemia

Hypercholesterolemia
Delivery Platform:
PDoV-GalNAc subcutaneous
Commercial Rights:
Global
STP135G formulated with our GalAhead™ delivery platform for subcutaneous administration.
We are developing STP135G as part of our cardiometabolic disease program.
Complement-mediated diseases
Complement-mediated diseases

Complement-mediated diseases
Delivery Platform:
GalAhead™ subcutaneous
Commercial Rights:
Global
STP144G comprises RNAi triggers targeting Complement Factor B, formulated with our GalAhead™ delivery platform for subcutaneous administration. We are developing STP144G for use in treating complement-mediated diseases. We maintain the global rights to develop and commercialize STP144G.

Delivery Platform:
PDoV-GalNAc subcutaneous
Commercial Rights:
Global
STP155G comprises siRNA targeting hepatitis B viral sequences formulated with our PDoV-GalNAc RNAi delivery platform for subcutaneous administration. We are developing STP155G for the treatment of hepatitis B. We maintain the global rights to develop and commercialize STP155G.
Notes: |
* denotes our core product |
|
** denotes orphan drug |
Abbreviations:
isSCC = cutaneous squamous cell carcinoma in situ;
BCC = basal cell carcinoma;
cSCC = metastatic cutaneous squamous cell carcinoma;
NSCLC = non-small cell lung cancer;
CRC = colorectal carcinoma;
BC = bladder cancer;
PSC = primary sclerosing cholangitis;
PNP = our polypeptide nanoparticle (PNP) RNAi delivery platform;
PNP-IT = PNP platform formulated for intratumoral administration;
PNP-IV = PNP platform formulated for intravenous administration;
PNP-ID= PNP platform formulated for intradermal administration;
GalAhead™= our GalNAc RNAi delivery platform that conjugates GalNAc moieties to RNAi triggers;
PDoV-GalNAc = our GalNAc RNAi delivery platform that conjugates GalNAc moieties to Peptide Docking Vehicle (PDoV) peptide linkers and up to two siRNAs to the peptide;
LNP = lipid nanoparticle (LNP) formulation for delivery of mRNA;
HPV = human papilloma virus;
HBV = hepatitis B virus;
OL China = out-licensed mainland China, Hong Kong, Macau and Taiwan rights under agreement with Walvax but we retain the rights for rest of the world;
MRCT = multi regional clinical trial in which we will be the sponsor for all clinical trial sites;
ID = Intradermal;
- Liver cancer (basket) includes cholangiocarcinoma, hepatocellular carcinoma, liver metastases etc.
- Siranomics filed an IND in China, which is currently awaiting approval from NMPA, for study sites in China. The study sites will be part of a global multicenter study for our Phase IIb clinical trial for isSCC.
- Siranomics expects to file an IND in China as part of the global multicenter clinical trials.
- Sirnaomics expects to file an IND solely for HCC in China as part of the global multicenter clinical trials.
- Studies in combination with anti-PD-(L)1 inhibitors conducted pursuant to collaborations with Innovent and Shanghai Junshi.
- Research and development conducted by our subsidiary RNAimmune.